SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Biogen Idec, Inc. (Massachusetts) Release: New Data From Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect for Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis